TrialJournal of cancer research and clinical oncology2010

Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma.

Takeshi Hara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.